Spotlight On... Can Shire make the most of Baxalta's hemophilia meds?; AZ brings new blood into corp comms; Stricter DTC oversight expected in India; and more...

Shire ($SHPG) CEO Flemming Ornskov says his own goals for cost savings, post-merger with Baxalta ($BXLT), are higher than the company's stated $500 million. But analysts are still skeptical of the deal; they're particularly worried about stepped-up competition in hemophilia with new meds hitting the market. More from FiercePharma

> AstraZeneca ($AZN) has some new faces on its global communications team, with Neil Burrows as head of global media relations and Ali Perkins as head of communications for global medicines development. Report

> Indian drugmakers expect stricter curbs on consumer advertising. Though DTC campaigns are technically prohibited, the laws have loopholes, experts say. Report

> Sanofi's ($SNY) Korean unit and LG Life Sciences are locked in a dispute over a co-promotion deal on LG's top diabetes meds. Report

> Antidepressant treatment helps diabetics control their blood sugar, a new study found, potentially spurring more patients with both disorders to seek treatment. Report

And Finally... Kids with Type 1 diabetes are finding comfort in American Girl dolls styled as diabetics. Report

Suggested Articles

Moving into the Final Four of the #FierceMadness drug name tournament, contenders from both Big Pharma and smaller companies remain evenly in play.

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.